North America Drug Delivery Market is expected to reach USD 823.55 billion by 2024 from USD 501.37 billion in 2016, at a CAGR of 6.4% in the forecast period 2017 to 2024.The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. Injectable drug delivery market has the largest market segment in Drug delivery market.

Access Full Report: http://databridgemarketresearch.com/reports/north-america-drug-delivery-market/JOHNSON & JOHNSON SERVICES, INC.:

Founded in 1886 and headquartered at New Brunswick, New Jersey, U.S.; Johnson & Johnson Services, Inc., is engaged in the development and marketing of healthcare products. The company operates through three business segments, such as, consumer, pharmaceutical, and medical devices. The pharmaceutical segment offers a wide range of products for five major therapeutic applications—immunology, infectious diseases, neuroscience, oncology, and cardiovascular & metabolic diseases. The consumer segment of the company offers various products pertaining to baby care, oral care, skin care, women’s health, and wound care.

Recent Developments:

1. In September 2016, Johnson & Johnson acquired Abbott Medical Optics (AMO), a completely-owned subsidiary of Abbott which consists of ophthalmic products in three segments of patient care: laser refractive surgery, cataract surgery, and consumer eye health.
2. In January 2017, for the treatment of patients suffering with marginal zone lymphoma (MZL) the U.S. Food and Drug Administration (FDA) approved the IMBRUVICA (ibrutinib).

NOVARTIS:

Founded in 1996 and headquartered at Basel, Switzerland. Novartis AG is a manufacturer of healthcare and pharmaceutical products. The company operates in five segments- Pharmaceuticals, Alcon (Eye Care), Sandoz (Generics), Vaccines, and Consumer Health. Through its pharmaceutical segment, the company develops various patented and innovative medicines in the field of oncology, primary care, cardio metabolic, immunology, dermatology, and established medicines (medicines for the treatment of rheumatoid arthritis and osteoarthritis, epilepsy, and high blood pressure).

Recent Developments:

1. In June 2017, Novartis announced that the European Commission has approved the inclusion of Treatment Free Remission (TFR) data in the Tasigna (nilotinib) Summary of Product characteristics. (SmPC).
2. In September 2016, Novartis announced that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.                                                                                   

F.HOFFMANN-LA ROCHE LTD:

Founded in 1896 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche Ltd. operates under two business segments—the Pharmaceuticals division (Roche Pharmaceuticals) and the Diagnostics division (Roche Diagnostics). Under its Pharmaceuticals segment, Roche provides a wide range of products for therapeutic areas such as oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche Diagnostics, on the other hand, offers its products through five sub segments, namely, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, Roche Tissue Diagnostics, and Roche Applied Science.

Recent Developments:

1. In October 2016, Roche announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumour has EGFR or ALK gene abnormalities.
2. In June 2016, Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with MabThera (rituximab) or a MabThera-containing regimen.